Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 1875928, 19 pages
https://doi.org/10.1155/2018/1875928
Review Article

Potential Application of Yokukansan as a Remedy for Parkinson’s Disease

1Department of Korean Internal Medicine, Dunsan Korean Medical Hospital, Daejeon University, Daejeon 35235, Republic of Korea
2Immunoregulatory Materials Research Center, Korea Research Institute of Bioscience and Biotechnology, 181 Ipsin-gil, Jeongeup-si, Jeonbuk 56212, Republic of Korea
3K-herb Research Center, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
4Department of Korean Neuropsychology, Dunsan Korean Medicine Hospital, Daejeon University, Daejeon 35235, Republic of Korea
5College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University, Gwangju 61186, Republic of Korea

Correspondence should be addressed to Horyong Yoo; moc.liamg@ooy.gnoyroh and Changjong Moon; rk.ca.mannohc@cnoom

Received 12 July 2018; Revised 27 November 2018; Accepted 10 December 2018; Published 20 December 2018

Academic Editor: Yoshiji Ohta

Copyright © 2018 Jung-Hee Jang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Poewe, K. Seppi, C. M. Tanner et al., “Parkinson disease,” Nature Reviews Disease Primers, vol. 3, p. 17013, 2017. View at Publisher · View at Google Scholar
  2. T. Hatano, N. Hattori, T. Kawanabe et al., “An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease,” Journal of Neural Transmission, vol. 121, no. 3, pp. 275–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Mizoguchi and Y. Ikarashi, “Multiple psychopharmacological effects of the traditional Japanese Kampo medicine Yokukansan, and the brain regions it affects,” Frontiers in Pharmacology, vol. 8, 2017. View at Google Scholar · View at Scopus
  4. Y. Ikarashi and K. Mizoguchi, “Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients,” Pharmacology & Therapeutics, vol. 166, pp. 84–95, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Hayashi, Y. Ishida, K. Okahara, and Y. Mitsuyama, “An Open-Label Trial of Yokukansan on Sleep Disturbance in Alzheimer's Disease and Other Dementia,” The Journal of Prevention of Alzheimer's Disease, vol. 2, no. 3, pp. 172–177, 2015. View at Google Scholar
  6. H. Shinno, Y. Inami, T. Inagaki, Y. Nakamura, and J. Horiguchi, “Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 3, pp. 881–885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Aizawa, T. Kanbayashi, Y. Saito et al., “Effects of yoku-kan-san-ka-chimpi-hange on the sleep of normal healthy adult subjects,” Psychiatry and Clinical Neurosciences, vol. 56, no. 3, pp. 303-304, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Shinno, M. Kamei, Y. Inami, J. Horiguchi, and Y. Nakamura, “Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 7, pp. 1749–1751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kawanabe, A. Yoritaka, H. Shimura, H. Oizumi, S. Tanaka, and N. Hattori, “Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 34, no. 2, pp. 284–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Teranishi, M. Kurita, S. Nishino et al., “Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: A blinded, randomized trial,” Journal of Clinical Psychopharmacology, vol. 33, no. 5, pp. 600–607, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Mizukami, T. Asada, T. Kinoshita et al., “A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia,” The International Journal of Neuropsychopharmacology, vol. 12, no. 2, pp. 191–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Iwasaki, T. Satoh-Nakagawa, M. Maruyama et al., “A randomized observer-blind, controlled trial of the traditional Chinese medicine yi-gan san for improvement of behavioral and psychological symptoms and activities of daily living dementia patients,” Journal of Clinical Psychiatry, vol. 66, no. 2, pp. 248–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Furukawa, N. Tomita, D. Uematsu et al., “Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease,” Geriatrics & Gerontology International, vol. 17, no. 2, pp. 211–218, 2017. View at Publisher · View at Google Scholar
  14. K. Okahara, Y. Ishida, Y. Hayashi et al., “Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 34, no. 3, pp. 532–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Hayashi, Y. Ishida, T. Inoue et al., “Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 34, no. 3, pp. 541–545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Monji, M. Takita, T. Samejima et al., “Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 33, no. 2, pp. 308–311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Nagata, E. Yokoyama, T. Yamazaki et al., “Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial,” Phytomedicine, vol. 19, no. 6, pp. 524–528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Miyaoka, R. Wake, M. Furuya et al., “Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: an open-label study,” Phytomedicine, vol. 20, no. 7, pp. 654–658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Sakamoto, H. Ujike, M. Takaki et al., “Adjunctive yokukansan treatment improved cognitive functions in a patient with schizophrenia,” The Journal of Neuropsychiatry and Clinical Neurosciences, vol. 25, no. 3, pp. E39–E40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Nakamura, K. Tajima, I. Kawagoe, M. Kanai, and H. Mitsuhata, “Efficacy of traditional herbal medicine Yokukansan on patients with neuropathic pain,” The Japanese Journal of Anesthesiology, vol. 58, no. 10, pp. 1248–1255, 2009. View at Google Scholar · View at Scopus
  21. T. Miyaoka, M. Furuya, H. Yasuda et al., “Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 3, pp. 761–764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Egashira, A. Nogami, K. Iwasaki et al., “Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: Possible involvement of GABA A - Benzodiazepine receptor complex,” Journal of Pharmacological Sciences, vol. 116, no. 3, pp. 316–320, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Ogawa, Y. Fujii, R. Sugiyama, and T. Konishi, “The role of the seven crude drug components in the sleep-promoting effect of Yokukansan,” Journal of Ethnopharmacology, vol. 177, pp. 19–27, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Miyagishi, M. Tsuji, A. Saito, K. Miyagawa, and H. Takeda, “Inhibitory effect of yokukansan on the decrease in the hippocampal excitatory amino acid transporter EAAT2 in stress-maladaptive mice,” Journal of Traditional and Complementary Medicine, vol. 7, no. 4, pp. 371–374, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Ito, N. Shin, T. Tsuchida, T. Okubo, and H. Norimoto, “Antianxiety-like effects of Chimpi (dried citrus peels) in the elevated open-platform test,” Molecules, vol. 18, no. 8, pp. 10014–10023, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Mizoguchi, Y. Tanaka, and T. Tabira, “Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: Involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex,” Journal of Ethnopharmacology, vol. 127, no. 1, pp. 70–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Yamaguchi, A. Tsujimatsu, H. Kumamoto et al., “Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress,” Journal of Ethnopharmacology, vol. 143, no. 2, pp. 533–539, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ueki, K. Mizoguchi, T. Yamaguchi et al., “Yokukansan Increases 5-HT1A Receptors in the Prefrontal Cortex and Enhances 5-HT1A Receptor Agonist-Induced Behavioral Responses in Socially Isolated Mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 726471, 9 pages, 2015. View at Publisher · View at Google Scholar
  29. A. Nogami, Y. Sakata, N. Uchida et al., “Effects of yokukansan on anxiety-like behavior in a rat model of cerebrovascular dementia,” Journal of Natural Medicines, vol. 65, no. 2, pp. 275–281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Ohno, H. Miyagishi, M. Tsuji et al., “Yokukansan, a traditional Japanese herbal medicine, enhances the anxiolytic effect of fluvoxamine and reduces cortical 5-HT2A receptor expression in mice,” Journal of Ethnopharmacology, vol. 216, pp. 89–96, 2018. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Shoji and K. Mizoguchi, “Brain region-specific reduction in c-Fos expression associated with an anxiolytic effect of yokukansan in rats,” Journal of Ethnopharmacology, vol. 149, no. 1, pp. 93–102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Ueki, K. Mizoguchi, T. Yamaguchi et al., “Yokukansan, a traditional Japanese medicine, decreases head-twitch behaviors and serotonin 2A receptors in the prefrontal cortex of isolation-stressed mice,” Journal of Ethnopharmacology, vol. 166, pp. 23–30, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Egashira, K. Iwasaki, A. Ishibashi et al., “Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 6, pp. 1516–1520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Uchida, N. Egashira, K. Iwasaki et al., “Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents,” Biological & Pharmaceutical Bulletin, vol. 32, no. 3, pp. 372–375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Sekiguchi, T. Yamaguchi, M. Tabuchi, Y. Ikarashi, and Y. Kase, “Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid β protein into mice,” Phytotherapy Research, vol. 23, no. 8, pp. 1175–1181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Tabuchi, K. Mizuno, K. Mizoguchi, T. Hattori, and Y. Kase, “Yokukansan and yokukansankachimpihange ameliorate aggressive behaviors in rats with cholinergic degeneration in the nucleus basalis of meynert,” Frontiers in Pharmacology, vol. 8, 2017. View at Google Scholar · View at Scopus
  37. H. Kanno, K. Sekiguchi, T. Yamaguchi et al., “Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats,” Journal of Pharmacy and Pharmacology, vol. 61, no. 9, pp. 1249–1256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Takeda, H. Iwaki, K. Ide, H. Tamano, and N. Oku, “Therapeutic effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient and pair-fed mice,” Brain Research Bulletin, vol. 87, no. 6, pp. 551–555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Tamano, F. Kan, N. Oku, and A. Takeda, “Ameliorative effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient young mice,” Brain Research Bulletin, vol. 83, no. 6, pp. 351–355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Tamano, E. Yusuke, K. Ide, and A. Takeda, “Influences of yokukansankachimpihange on aggressive behavior of zinc-deficient mice and actions of the ingredients on excessive neural exocytosis in the hippocampus of zinc-deficient rats,” Journal of Experimental Animal Science, vol. 65, no. 4, pp. 353–361, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Tabuchi, T. Yamaguchi, S. Iizuka, S. Imamura, Y. Ikarashi, and Y. Kase, “Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease,” Journal of Ethnopharmacology, vol. 122, no. 1, pp. 157–162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Nogami-Hara, M. Nagao, K. Takasaki et al., “The Japanese Angelica acutiloba root and yokukansan increase hippocampal acetylcholine level, prevent apoptosis and improve memory in a rat model of repeated cerebral ischemia,” Journal of Ethnopharmacology, vol. 214, pp. 190–196, 2018. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Uchida, K. Takasaki, Y. Sakata et al., “Cholinergic involvement and synaptic dynamin 1 expression in yokukansan-mediated improvement of spatial memory in a rat model of early alzheimer's disease,” Phytotherapy Research, vol. 27, no. 7, pp. 966–972, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Yamada, M. Hayashida, Q. Zhao et al., “Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice,” Journal of Ethnopharmacology, vol. 135, no. 3, pp. 737–746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Mizoguchi, H. Shoji, Y. Tanaka, and T. Tabira, “Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats,” Neuroscience, vol. 177, pp. 127–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Ikarashi, S. Iizuka, S. Imamura et al., “Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats,” Biological & Pharmaceutical Bulletin, vol. 32, no. 10, pp. 1701–1709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Furuya, T. Miyaoka, T. Tsumori et al., “Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat,” Journal of Neuroinflammation, vol. 10, p. 145, 2013. View at Google Scholar · View at Scopus
  48. Y. Liu, T. Nakamura, T. Toyoshima et al., “Ameliorative effects of yokukansan on behavioral deficits in a gerbil model of global cerebral ischemia,” Brain Research, vol. 1543, pp. 300–307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Suzuki, H. Mitsuhata, M. Yuzurihara, and Y. Kase, “Antiallodynic effect of herbal medicine yokukansan on peripheral neuropathy in rats with chronic constriction injury,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, p. 953459, 2012. View at Google Scholar · View at Scopus
  50. S. Ebisawa, T. Andoh, Y. Shimada, and Y. Kuraishi, “Yokukansan Improves Mechanical Allodynia through the Regulation of Interleukin-6 Expression in the Spinal Cord in Mice with Neuropathic Pain,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 870687, 8 pages, 2015. View at Publisher · View at Google Scholar
  51. K. Sekiguchi, H. Kanno, T. Yamaguchi, Y. Ikarashi, and Y. Kase, “Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system,” Brain Research Bulletin, vol. 89, no. 5-6, pp. 151–158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Nakatani, M. Tsuji, T. Amano et al., “Neuroprotective effect of yokukansan against cytotoxicity induced by corticosterone on mouse hippocampal neurons,” Phytomedicine, vol. 21, no. 11, pp. 1458–1465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Tateno, W. Ukai, T. Ono, S. Saito, E. Hashimoto, and T. Saito, “Neuroprotective effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neurons,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32, no. 7, pp. 1704–1707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Kawakami, H. Kanno, Y. Ikarashi, and Y. Kase, “Yokukansan, a kampo medicine, protects against glutamate cytotoxicity due to oxidative stress in PC12 cells,” Journal of Ethnopharmacology, vol. 134, no. 1, pp. 74–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. Y.-R. Zhao, W. Qu, W.-Y. Liu et al., “YGS40, an active fraction of Yi-Gan San, reduces hydrogen peroxide-induced apoptosis in PC12 cells,” Chinese Journal of Natural Medicines, vol. 13, no. 6, pp. 438–444, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Terawaki, Y. Ikarashi, K. Sekiguchi, Y. Nakai, and Y. Kase, “Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells,” Journal of Ethnopharmacology, vol. 127, no. 2, pp. 306–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Matsunaga, T. Kishi, and N. Iwata, “Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials,” Journal of Alzheimer's Disease, vol. 54, no. 2, pp. 635–643, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. A.-R. Doo, S.-N. Kim, J.-Y. Park et al., “Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo,” Journal of Ethnopharmacology, vol. 131, no. 2, pp. 433–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. B. R. Bloem, I. Irwin, O. J. S. Buruma et al., “The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease,” Journal of the Neurological Sciences, vol. 97, no. 2-3, pp. 273–293, 1990. View at Publisher · View at Google Scholar · View at Scopus
  60. K. F. Tipton and T. P. Singer, “Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds,” Journal of Neurochemistry, vol. 61, no. 4, pp. 1191–1206, 1993. View at Publisher · View at Google Scholar · View at Scopus
  61. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” The Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Moreno, N. Hernández-Beltrán, D. Munévar, and A. Gutiérrez-Alvarez, “Dolor neuropático central en enfermedad de Parkinson,” Neurología, vol. 27, no. 8, pp. 500–503, 2012. View at Publisher · View at Google Scholar
  63. C. C. H. Aquino and A. E. Lang, “Tardive dyskinesia syndromes: Current concepts,” Parkinsonism & Related Disorders, vol. 20, no. 1, pp. S113–S117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. K.-B. Hong, Y. Park, and H. J. Suh, “Sleep-promoting effects of the GABA/5-HTP mixture in vertebrate models,” Behavioural Brain Research, vol. 310, pp. 36–41, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. N. J. Diederich, C. G. Goetz, and G. T. Stebbins, “Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model,” Movement Disorders, vol. 20, no. 2, pp. 130–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. J. B. Malick, E. Doren, and A. Barnett, “Quipazine-induced head-twitch in mice,” Pharmacology Biochemistry & Behavior, vol. 6, no. 3, pp. 325–329, 1977. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Fernandes, C. R. McKittrick, S. E. File, and B. S. McEwen, “Decreased 5-HT(1A) and increased 5-HT(2A) receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety,” Psychoneuroendocrinology, vol. 22, no. 7, pp. 477–491, 1997. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Bedard and C. J. Pycock, “'Wet-Dog' shake behaviour in the rat: A possible quantitative model of central 5-hydroxytryptamine activity,” Neuropharmacology, vol. 16, no. 10, pp. 663–670, 1977. View at Publisher · View at Google Scholar · View at Scopus
  69. I. Lucki, M. S. Nobler, and A. Frazer, “Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat,” The Journal of Pharmacology and Experimental Therapeutics, vol. 228, no. 1, pp. 133–139, 1984. View at Google Scholar · View at Scopus
  70. A. H. Ford, “Neuropsychiatric aspects of dementia,” Maturitas, vol. 79, no. 2, pp. 209–215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. B. A. Stein-Behrens, E. M. Elliott, C. A. Miller, J. W. Schilling, R. Newcombe, and R. M. Sapolsky, “Glucocorticoids exacerbate kainic acid-induced extracellular accumulation of excitatory amino acids in the rat hippocampus,” Journal of Neurochemistry, vol. 58, no. 5, pp. 1730–1735, 1992. View at Publisher · View at Google Scholar · View at Scopus
  72. A. V. Terry Jr. and J. J. Buccafusco, “The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development,” The Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 821–827, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. E.-H. Chung, K. Iwasaki, K. Mishima, N. Egashira, and M. Fujiwara, “Repeated cerebral ischemia induced hippocampal cell death and impairments of spatial cognition in the rat,” Life Sciences, vol. 72, no. 4-5, pp. 609–619, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. H. R. Santos, “The Magnitude of 7 Nicotinic Receptor Currents in Rat Hippocampal Neurons Is Dependent upon GABAergic Activity and Depolarization,” The Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 1, pp. 376–385, 2006. View at Publisher · View at Google Scholar
  75. J.-P. Sigle, J. Zander, A. Ehret, J. Honegger, R. Jackisch, and T. J. Feuerstein, “High potassium-induced activation of choline-acetyltransferase in human neocortex: Implications and species differences,” Brain Research Bulletin, vol. 60, no. 3, pp. 255–262, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. P. J. Yao, M. Zhu, E. I. Pyun et al., “Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease,” Neurobiology of Disease, vol. 12, no. 2, pp. 97–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Schousboe, U. Sonnewald, G. Civenni, and G. Gegelashvili, “Role of astrocytes in glutamate homeostasis: Implications for excitotoxicity,” Advances in Experimental Medicine and Biology, vol. 429, pp. 195–206, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. R. A. Kohman, T. K. Bhattacharya, C. Kilby, P. Bucko, and J. S. Rhodes, “Effects of minocycline on spatial learning, hippocampal neurogenesis and microglia in aged and adult mice,” Behavioural Brain Research, vol. 242, no. 1, pp. 17–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Katahira, M. Sunagawa, D. Watanabe et al., “Antistress effects of Kampo medicine “Yokukansan” via regulation of orexin secretion,” Neuropsychiatric Disease and Treatment, vol. 13, pp. 863–872, 2017. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Strano, A. Fanciulli, M. Rizzo et al., “Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment,” Journal of the Neurological Sciences, vol. 370, pp. 251–255, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Falquetto, M. Tuppy, S. R. Potje, T. S. Moreira, C. Antoniali, and A. C. Takakura, “Cardiovascular dysfunction associated with neurodegeneration in an experimental model of Parkinson's disease,” Brain Research, vol. 1657, pp. 156–166, 2017. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Ariza, L. Sisdeli, C. C. Crestani, R. Fazan, and M. C. Martins-Pinge, “Dysautonomias in parkinson’s disease: Cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 308, no. 3, pp. H250–H257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Yeo, R. Singh, M. Gundeti, J. M. Barua, and J. Masood, “Urinary tract dysfunction in Parkinson's disease: A review,” International Urology and Nephrology, vol. 44, no. 2, pp. 415–424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Ohtomo, D. Umino, M. Takada, S. Niijima, S. Fujinaga, and T. Shimizu, “Traditional Japanese medicine, Yokukansan, for the treatment of nocturnal enuresis in children,” Pediatrics International, vol. 55, no. 6, pp. 737–740, 2013. View at Publisher · View at Google Scholar · View at Scopus